Bookmark this page — track observed submission-to-acceptance timing, FWCI and field-normalized citation data for this journal in one view.

Journal decision profile

Breast Cancer Research and Treatment

Biochemistry, Genetics and Molecular Biology · Medicine
Springer Science+Business MediaNetherlandspISSN 0167-6806eISSN 1573-7217
Checking system sharing availability.Visit homepage
Journal Metrics Score
i
Journal Metrics ScoreThe raw score is citations received in the latest complete year by works from the two previous years, divided by the number of those works. It is calculated from OpenAlex open data (CC0) and is not a percentage grade.
2026
3.2

Journal Metrics Score 2026 · 2021–2024 window citedness 3.65.

Submission-to-acceptance
i
Submission-to-acceptanceCalendar days between the received and accepted dates reported in recent PubMed records. This interval includes editorial handling and author revisions, so it is not time to first decision or pure peer-review time.
PUBMED
84 daysmedian

Middle 50%: 65–112 days

100 of 100 PubMed-indexed articles · 100% coverage · 2024–2025

Indicative APC
i
Indicative APCThis journal-level estimate comes from the OpenAlex source record. It is not a verified quote and may exclude taxes, waivers, society discounts, or article-type charges. Check the journal's official website before deciding.
OPENALEX · VERIFY
$3,790

Journal-level estimate only. Verify current charges, taxes, waivers, discounts, and article-type fees with the journal.

At a glance

Journal decision profile

Each spoke is a 0–100 percentile within a comparable journal cohort—not a percentage grade or a single black-box rating.

Relative profile

Metrics ScoreThe raw 2026 Journal Metrics Score is the recent two-year citation average shown above. The radar converts it to a 0–100 cohort percentile: farther out means a higher score than more comparable journals. It is not a percentage grade.iSource outputThe raw rank compares lifetime output inside the journal’s leading-topic source set. The radar then compares that rank position across Decision Profile journals in the same primary OpenAlex field; when that field has too few profiles, it uses the broader profile set. Farther out means relatively more output, not better research quality.iTop 10% shareThe share of recent papers in the global top 10% for citations after comparing papers of the same type, publication year, and subfield. The radar converts that share to a 0–100 cohort percentile; it does not predict how a new paper will perform.iMedian FWCICitation performance of the middle recent paper after field, year, and work type are considered. A raw FWCI of 1.0 is the expected citation level for comparable papers; the radar shows its 0–100 cohort percentile.iSubmission-to-acceptanceCalendar days from the received date to the accepted date in recent PubMed records. This includes editorial handling and author revisions, so it is not the time to first decision and not pure peer-review time. The radar uses a 0–100 cohort percentile with shorter observed timing plotted farther out; it does not measure review quality.iOutput volumeAverage works published per year in the recent analysis window, converted to a 0–100 cohort percentile. Farther out means the journal publishes more papers; it does not mean those papers are better.i
Cost is intentionally excluded. Missing APC data is never converted to a zero-dollar fee or a fabricated cost score.

Raw values behind the shape

Always visible
Metrics Score
i
Metrics ScoreThe 2026 raw Journal Metrics Score shown above. The bar is its 0–100 percentile within the radar's comparable journal cohort; it is not a percentage score.
3.22026 · OPENALEX
Source output rank
i
Source output rankThis lifetime journal-wide output rank compares works published by the OpenAlex source with sources associated with the journal’s leading topic. More output does not mean higher quality.
#43 / 1,355LIFETIME OUTPUT
Highly cited papers
i
Highly cited papersShare of recent works in the global top 10% for citations after comparing papers of the same type, publication year, and subfield.
12.2%FIELD-NORMALIZED TOP 10%
Field-normalized impact
i
Field-normalized impactCitation performance of the middle recent paper after field, year, and work type are considered. A raw FWCI of 1.0 is the expected level for comparable work.
0.92MEDIAN FWCI
Submission-to-acceptance
i
Submission-to-acceptanceReceived-to-accepted calendar days from qualified PubMed records. It includes editorial handling and author revisions; it is not time to first decision or pure peer-review time.
84 daysIQR 65–112 DAYS
Recent output
i
Recent outputAverage works published per year across the complete analysis window. This is a volume measure, not a quality score.
387 / yr2021–2024 AVG
Field-normalized top 10% share12.2%

189 of 1,549 works · same type, year & subfield

Field-normalized top 1% share0.3%

5 works · same type, year & subfield

Median FWCI0.92×

Below field-year expectation

Source output rank#43

of 1,355 topic-associated OpenAlex sources by lifetime output

What does Median FWCI mean?

FWCI compares papers with the same publication year, type, and field. 1.0 is the world average; above 1.0 is above expectation. This journal's median is 0.92, so its typical recent paper runs about 8% below its field benchmark.

What does Top 10% Share mean?

12.2% of recent papers rank in the global top 10% after field normalization. This is easier to compare across specialties than raw citation totals.

Publishing pattern

Publication volume and article mix

Volume is separated from citation accumulation so newer papers are not presented as weaker simply because they are newer.

Works published by year

OpenAlex source records · 2016–2025

4152016
5352017
4542018
4232019
5102020
4292021
3782022
3602023
3822024
2962025

Recent work-type mix

1,549 OpenAlex works · 2021–2024

Article93.8%
Review2.8%
Erratum1.7%
Letter1.2%
Retraction0.3%
Editorial0.1%
OpenAlex article is broader than “original research.” PubMed Publication Types can add case-report and clinical-study detail.
Fit signals

Topics and medical subject coverage

OpenAlex topics show research communities; MeSH keeps the medical taxonomy recognizable.

Major MeSH signals

PubMed-indexed works
Breast NeoplasmsTriple Negative Breast NeoplasmsNeoadjuvant TherapyCancer SurvivorsCarcinoma, Intraductal, NoninfiltratingCarcinoma, Ductal, BreastBiomarkers, TumorReceptor, ErbB-2Antineoplastic Combined Chemotherapy Protocols

Leading OpenAlex topics

2021–2024 works
Breast Cancer Treatment Studies384
BRCA gene mutations in cancer92
Cancer Risks and Factors75
HER2/EGFR in Cancer Research75
Advanced Breast Cancer Therapies69
Global Cancer Incidence and Screening61
Cancer survivorship and care51
Cancer Immunotherapy and Biomarkers44
Breast Lesions and Carcinomas34
Estrogen and related hormone effects30
Methodology: OpenAlex snapshot 2026-08-12. FWCI, percentile badges, topics, and type mix use 1,549 works published 2021–2024. Radar normalization is versioned in the cached profile, and no cost score is assigned without reliable APC data.

Recommended alternatives

Candidates share the leading OpenAlex topic, then subfield or field when needed, and are ranked by current Journal Metrics Score.

OpenAlex topic-neighbor model · Preview
Npj Breast CancerTopic-neighbor alternative5.7Metrics Score146dIQR 100–216dSubmission → acceptance$$$Cost*Breast Cancer ResearchTopic-neighbor alternative5.3Metrics Score138dIQR 83–196dSubmission → acceptance$$$Cost*Translational Breast Cancer ResearchTopic-neighbor alternative3.4Metrics Score—Submission → acceptance$—Cost*Breast CancerTopic-neighbor alternative2.8Metrics Score111dIQR 76–155dSubmission → acceptance$$$Cost*European Journal of CancerTopic-neighbor alternative2.7Metrics Score77dIQR 59–119dSubmission → acceptance$$$Cost*World Journal of OncologyTopic-neighbor alternative2.6Metrics Score—Submission → acceptance$—Cost*

More alternative journals

Clinical Breast CancerBreast Cancer-Basic and Clinical ResearchJournal of the Egyptian National Cancer InstituteBreastJournal of Breast CancerBreast Cancer-Targets and Therapy

* Cost is indicative only. APCs, taxes, waivers, and member discounts can change—always verify on the journal's official website.

Subject Category Quartiles

Quartiles computed within each OpenAlex subfield
CategoryQuartile
Cancer ResearchQ2
GeneticsQ1
OncologyQ2
Pathology and Forensic MedicineQ1

Considering submitting to Breast Cancer Research and Treatment?

Use your manuscript title to find AI-ranked journals with related recent work, fit reasons, risks, and submission strategy.

Match my manuscript →
Q1
Subfield Quartile
B3
CAS Block

Ranking and source check

#243
of 853 Oncology field journals
#230
among Q1 Oncology journals

Confirm the exact title and ISSNs against the publisher homepage before a high-stakes submission decision.

View all Oncology journals →View Q1 Oncology journals →

Journal Details

OpenAlex Works
12,469
H-Index
221
Fully Open Access
No
Recent OA Works
3,738
Subject Areas
Cancer ResearchGeneticsOncologyPathology and Forensic Medicine

Source: the current OpenAlex source record. OpenAlex works can include multiple work types. Fully Open Access is a source-level flag. Recent OA Works is summed from OpenAlex's counts_by_year series (up to the latest ten years); it is not a lifetime OA percentage. Any APC shown here is an indicative OpenAlex value—verify current charges on the journal's official website.

Related Guides

Field Rankings
Best Oncology Journals: Journal Metrics Scores and Cancer Research Guide
12 min read
Field Rankings
Archived Chemistry Journal Selection Guide
14 min read
Field Rankings
Archived Biology Journal Selection Guide
14 min read
Field Rankings
Archived Medical Journal Selection Guide
14 min read
Back to Search